Article

A system-wide approach to monitor responses to synergistic BRAF and EGFR inhibition in colorectal cancer cells

2017-09-27

Abstract excerpt

Intrinsic and/or acquired resistance represents one of the great challenges in targeted cancer therapy. A deeper understanding of the molecular biology of cancer has resulted in more efficient strategies, where one or multiple drugs are adopted in novel therapies to tackle resistance. This beneficial effect of using combination treatments has also been observed in colorectal cancer patients harboring the BRAF(V600...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9d084565-32bb-5f5d-a6ca-b8cfa13a17a7
DOI: 10.1101/194845

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A system-wide approach to monitor responses to synergistic BRAF and EGFR inhibition in colorectal cancer cellsDOI 10.1101/194845Read

A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells.Semantic proximity Read

Multi-omics analysis delineates resistance mechanisms associated with BRAF inhibition in melanoma cells.Semantic proximity Read

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity Read

BRAFV600E patient derived colon cancer organoids identify biomarkers of response to EGFR and BRAF inhibition and replicate clinical data.Semantic proximity Read

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.Semantic proximity Read

Signaling and transcriptional dynamics underlying early adaptation to oncogenic BRAF inhibitionSemantic proximity Read

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.Semantic proximity Read

Current and Emerging Treatment Paradigms in Colorectal Cancer: Integrating Hallmarks of CancerSemantic proximity Read

Pharmacoproteomic characterisation of human colon and rectal cancerSemantic proximity Read

Cellular mechanisms of acquired drug resistance against regorafenib in colon cancer cellsSemantic proximity Read

The past, present, and future treatment of BRAFV600-mutant metastatic colorectal cancer: A comprehensive review.Semantic proximity Read

Same mutation, different fates: The Yin-Yang of BRAF-driven therapeutic responses in melanoma and colorectal cancer.Semantic proximity Read